



Cara Therapeutics  
Investor Relations Department  
107 Elm St. 9th Flr  
Stamford, CT 06902  
United States

Visit IR website [↗](#)  
Sign-up for Email alerts [↗](#)

#### NASDAQ: CARA

Last Trade:	12.40
Trade Time:	4:00 PM ET Oct 18, 2017
Change:	-0.08 <span style="color: red;">↓</span> (-0.641%)
Day Range	12.18 - 12.61
52-Week Range	5.85 - 28.50
Volume	774,334

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Cara Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors.

We are developing a novel and proprietary class of product candidates that target the body's peripheral nervous system and have demonstrated efficacy in patients with moderate-to-severe pain without inducing many of the undesirable side effects typically associated with currently available pain therapeutics. Our most advanced product candidate, intravenous, or I.V... [\(more\)](#)

## Stock Performance



### Press Releases [\[ View all \]](#)

- Oct 17, 2017*  
[Cara Therapeutics Announces Participation in ANESTHESIOLOGY@ 2017](#)
- Oct 16, 2017*  
[Cara Therapeutics to Present Data at Kidney Week 2017](#)
- Oct 16, 2017*  
[Cara Therapeutics Announces Successful End-of-Phase 2 Meeting with FDA for I.V. CR845 in Chronic Kidney Disease-Associated Pruritus](#)
- Oct 4, 2017*  
[Cara Therapeutics to Present at the Janney Montgomery Scott Osteoarthritis Pain Conference](#)
- Aug 31, 2017*  
[Cara Therapeutics to Participate in September Medical Meetings](#)

### Financials [\[ View all \]](#)

- Mar 10, 2017*  
[Annual Report \(10-K\)](#)
- May 10, 2017*  
[Proxy Statement \(DEF 14A\)](#)
- Aug 3, 2017*  
[Quarterly Report \(10-Q\)](#)
- May 4, 2017*  
[Quarterly Report \(10-Q\)](#)
- Nov 4, 2016*  
[Quarterly Report \(10-Q\)](#)